Motor neurone disease (MND) affects approximately 5 per 100,000 people in the UK and tends to develop in mid to late life. As the name suggests, the disorder affects the motor system, such that muscles become wasted and weak. Muscles of the limbs, trunk and speech can all be affected in this relentlessly progressive condition.
The treatment of MND is woefully inadequate at present and there is a pressing need to develop new therapies.
LiCALS Open Label - OPEN TO RECRUITMENT JANUARY 2011
Patients who have completed their treatment on the placebo controlled study are given the option to carry on with open label treatment.